SIGA Technologies Inc (SIGA)
NASDAQ:SIGA
Want to see SIGA full AI Analyst Report?
SIGA Stock Chart & Stats
$6.77
-$0.07(-1.11%)
At close: 4:00 PM EST
$6.77
-$0.07(-1.11%)
Day’s Range― - ―
52-Week Range$4.10 - $9.62
Previous CloseN/A
Volume59.56K
Average Volume (3M)461.52K
Market Cap
$341.41M
Enterprise Value$190.74M
Total Cash (Recent Filing)$145.56M
Total Debt (Recent Filing)$638.23K
Price to Earnings (P/E)16.5
Beta1.40
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.29
Shares Outstanding71,724,100
10 Day Avg. Volume376,632
30 Day Avg. Volume461,516
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)2.20
Price to Sales (P/S)4.62
P/FCF Ratio10.15
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue2.03
Enterprise Value/Gross Profit3.11
Enterprise Value/Ebitda7.78
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.7
Revenue Forecast (FY)$66.31M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And No DebtA ~ $146M cash balance and zero reported debt provide durable financial flexibility and a multi-quarter runway even after a special dividend. This supports continued manufacturing readiness, optional capital deployment, and R&D/pipeline funding despite uneven revenue cadence.
Near-term Revenue Visibility From Institutional OrdersConfirmed Q2 deliveries (≈$13M oral order plus SNS IV shipments) materially improve near-term top-line visibility versus purely speculative demand. Secured institutional orders reduce short-term revenue uncertainty and prove continued government and international procurement relevance.
Pipeline Progress (pediatric IND, PEP Pathway)Advancing pediatric Phase 1 and targeting an FDA PEP submission within 12 months are structural milestones that can broaden labeled use and diversify demand beyond stockpiles. Successful regulatory progress would create new commercial channels and reduce reliance on episodic government procurements.
Bears Say
Sharp Revenue ContractionSteep multi-period revenue declines (≈32% in 2025 and ~84% TTM) signal demand concentration and vulnerability to procurement timing. Sustained or recurrent declines would erode operating leverage, challenge margin sustainability, and heighten execution risk for commercialization investments.
Large TTM Net Loss And Profitability VolatilityAn outsized TTM net loss, despite historically high gross margins, creates volatility between accounting losses and cash flow. If losses persist, they could deplete liquidity or force trade-offs in R&D and manufacturing scale-up, weakening long-term commercial execution despite current cash buffers.
Regulatory Setback In Europe (MPOXX)CHMP's recommendation to withdraw the MPOXX indication is a structural regulatory headwind that can limit commercial labeling and market access in Europe. Implementation steps and diminished regulatory standing could reduce ex-U.S. revenue potential and complicate future approvals or partnerships.
SIGA Technologies News
SIGA FAQ
What was SIGA Technologies Inc’s price range in the past 12 months?
SIGA Technologies Inc lowest stock price was $4.09 and its highest was $9.62 in the past 12 months.
What is SIGA Technologies Inc’s market cap?
SIGA Technologies Inc’s market cap is $341.41M.
When is SIGA Technologies Inc’s upcoming earnings report date?
SIGA Technologies Inc’s upcoming earnings report date is Jul 30, 2026 which is in 60 days.
How were SIGA Technologies Inc’s earnings last quarter?
SIGA Technologies Inc released its earnings results on May 07, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.05.
Is SIGA Technologies Inc overvalued?
According to Wall Street analysts SIGA Technologies Inc’s price is currently Overvalued.
Does SIGA Technologies Inc pay dividends?
SIGA Technologies Inc pays a Notavailable dividend of $0.6 which represents an annual dividend yield of N/A. See more information on SIGA Technologies Inc dividends here
What is SIGA Technologies Inc’s EPS estimate?
SIGA Technologies Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SIGA Technologies Inc have?
SIGA Technologies Inc has 71,724,100 shares outstanding.
What happened to SIGA Technologies Inc’s price movement after its last earnings report?
SIGA Technologies Inc reported an EPS of -$0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.48%.
Which hedge fund is a major shareholder of SIGA Technologies Inc?
Currently, no hedge funds are holding shares in SIGA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SIGA Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Increased
By 132.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.66%
12-Months-Change
Fundamentals
Return on Equity
10.62%
Trailing 12-Months
Asset Growth
-11.20%
Trailing 12-Months
Company Description
SIGA Technologies Inc
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
SIGA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally positive strategic and financial position driven by a strong cash balance, shareholder-friendly capital return, confirmed near-term international orders, regional commercial expansion via an exclusive Hikma agreement, and concrete pipeline progress (pediatric IND and PEP pathway). Offsetting these positives are the quarter's minimal deliveries and lumpy revenue profile, a small quarterly loss, a CHMP recommendation to withdraw the MPOXX indication in Europe, and slower progress toward a new U.S. government contract. Overall, the positives (liquidity, contracts, partnerships, and pipeline momentum) outweigh the near-term operational and regulatory headwinds.View all SIGA earnings summariesTechnical Analysis
Ownership Overview
1.58% Insiders
12.53% Mutual Funds
11.30% Other Institutional Investors
63.89% Public Companies and
Individual Investors